Luminex Corporation (NASDAQ:LMNX)‘s stock had its “hold” rating restated by equities researchers at Jefferies Group LLC in a research report issued on Friday. They currently have a $21.00 price target on the medical instruments supplier’s stock. Jefferies Group LLC’s price objective would indicate a potential upside of 2.64% from the stock’s current price. Jefferies Group also issued estimates for Luminex Corporation’s Q1 2018 earnings at $0.17 EPS, Q2 2018 earnings at $0.15 EPS, Q3 2018 earnings at $0.15 EPS and Q4 2018 earnings at $0.16 EPS.

Other research analysts also recently issued reports about the company. Zacks Investment Research raised Luminex Corporation from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a research note on Monday, July 17th. TheStreet downgraded Luminex Corporation from a “b” rating to a “c+” rating in a research note on Monday, August 7th. ValuEngine upgraded Luminex Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th. Finally, BidaskClub cut Luminex Corporation from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and one has given a strong buy rating to the stock. Luminex Corporation has a consensus rating of “Hold” and an average price target of $20.00.

Shares of Luminex Corporation (NASDAQ:LMNX) traded up 0.99% during midday trading on Friday, reaching $20.46. 126,278 shares of the company’s stock were exchanged. The company’s 50-day moving average is $20.07 and its 200-day moving average is $20.05. Luminex Corporation has a one year low of $17.64 and a one year high of $22.27. The stock has a market cap of $901.69 million, a P/E ratio of 63.34 and a beta of 0.29.

Luminex Corporation (NASDAQ:LMNX) last announced its earnings results on Monday, August 7th. The medical instruments supplier reported $0.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.09 by $0.11. The business had revenue of $76.50 million during the quarter, compared to the consensus estimate of $75.45 million. Luminex Corporation had a return on equity of 4.81% and a net margin of 4.72%. The business’s quarterly revenue was up 19.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.33 EPS. Equities analysts expect that Luminex Corporation will post $0.53 earnings per share for the current fiscal year.

WARNING: This article was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/10/21/luminex-corporation-lmnx-receives-hold-rating-from-jefferies-group-llc.html.

In related news, Director Robert J. Cresci sold 19,631 shares of the business’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $18.98, for a total transaction of $372,596.38. Following the completion of the sale, the director now directly owns 260,358 shares in the company, valued at $4,941,594.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.90% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Pinebridge Investments L.P. increased its position in shares of Luminex Corporation by 8.3% during the second quarter. Pinebridge Investments L.P. now owns 5,266 shares of the medical instruments supplier’s stock worth $111,000 after purchasing an additional 405 shares in the last quarter. Sei Investments Co. increased its position in shares of Luminex Corporation by 10.9% during the first quarter. Sei Investments Co. now owns 5,946 shares of the medical instruments supplier’s stock worth $110,000 after purchasing an additional 582 shares in the last quarter. State of Alaska Department of Revenue increased its position in shares of Luminex Corporation by 92.1% during the second quarter. State of Alaska Department of Revenue now owns 7,895 shares of the medical instruments supplier’s stock worth $166,000 after purchasing an additional 3,785 shares in the last quarter. Mason Street Advisors LLC increased its position in shares of Luminex Corporation by 0.5% during the first quarter. Mason Street Advisors LLC now owns 8,713 shares of the medical instruments supplier’s stock worth $160,000 after purchasing an additional 46 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Luminex Corporation by 37.4% during the second quarter. SG Americas Securities LLC now owns 9,726 shares of the medical instruments supplier’s stock worth $205,000 after purchasing an additional 2,649 shares in the last quarter. Hedge funds and other institutional investors own 78.12% of the company’s stock.

Luminex Corporation Company Profile

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Receive News & Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.